Artigo
Oxazolidinone susceptibility patterns for 2005: International report from the Zyvox (R) Annual Appraisal of Potency and Spectrum study
Fecha
2007-03-01Registro en:
International Journal of Antimicrobial Agents. Amsterdam: Elsevier B.V., v. 29, n. 3, p. 295-301, 2007.
0924-8579
10.1016/j.ijantimicag.2006.09.025
WOS:000244941300010
Autor
Ross, James E.
Fritsche, Thomas R.
Sader, Helio S. [UNIFESP]
Jones, Ronald N.
Institución
Resumen
The international (non-USA) ZAAPS Program has accumulated 4 years of linezolid resistance surveillance results tracking infections caused by organisms with evolving resistance profiles. the major organism groups monitored were: Staphylococcus aureus and coagulase-negative staphylococci (including methicillin [oxacill in] -resistant strains), enterococci (including vancomycin-resistant [VRE] strains), Streptococcus pneumoniae (including multidrug-resistant [MDR] strains), viridans group streptococci and P-haemolytic streptococci (4209 isolates overall). No linezolid-resistant strains were detected from the 16 monitored nations participating in 2005, consistent with previously reported 2002-2004 results. Linezolid remains highly active against Gram-positive strains including MRSA (MIC90, 2mg/L). With MDR in Gram-positive organisms increasing in prevalence, continued surveillance of linezolid appears to be prudent practice as linezolid becomes more widely prescribed for these difficult-to-treat infections. (c) 2007 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.